AtheroGenics halts high-dose AGI-1067 in trial

AtheroGenics announced on Friday that it would halt the use of the high dose of the experimental anti-inflammatory AGI-1067 in a clinical trial after scrutinizing the data on liver-related side effects. Studies of the 75 mg and 150 mg doses will continue. Earlier this year AtheroGenics announced layoffs after AstraZeneca dumped its $1 billion development pact for the drug after AGI-1067 failed studies as a treatment for heart disease.

- see this release
- check out the AP report on the trial

Related articles:
Failed AtheroGenics drug may work as diabetes therapy. Report
AtheroGenics extends waiting period on drug data. Report
Speculation heats up on fate of AGI-1067. Report
AtheroGenics inks billion-dollar licensing deal. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.